Webinar: Strategies to Overcome the Physical and Biological Barriers Associated with Pulmonary Drug

Title: ISAM Webinar: Strategies to Overcome the Physical and Biological Barriers Associated with Pulmonary Drug Delivery

Wednesday, 14th September 2022

Presenter: David Cipolla, PhD
David Cipolla is the VP of Research at Insmed Incorporated

Facilitators:

• Jessica Oakes
• CarstenEhrhardt
• Barbara Rothen-Rutishauser (ISAM president)

Webinar content

The past half-century has seen the emergence of sophisticated inhaled device technologies, including MDIs, DPIs, nebulizers and soft mist inhalers. When used properly, these technologies can facilitate delivery of therapeutics consistently and at high efficiency to the lung, bypassing oropharyngeal deposition. Novel chemistry or nanoparticle formulation technologies can be used in combination with these inhalation technologies to further improve treatment of lung disease. For example, strategies to overcome degradation and clearance mechanisms, or to reduce the rate of systemic absorption, can lead to prolonged retention of drug at the active site, which can extend duration of effect. Additionally, these technologies can improve tolerability of administration or facilitate uptake within cells to access intracellular targets. This paper describes the physical and biological barriers of pulmonary drug delivery and provides recent examples of formulation technologies or drug chemistry modifications to overcome those barriers.

About the presenter

David is the VP of Research at Insmed Incorporated, where he is part of a team developing novel, targeted therapies to help serve the critical unmet needs of patients battling serious rare diseases. Prior to joining Insmed in 2018, David worked at Aradigm (1996 to 2018) covering all phases of product development and led the development of preclinical research, CMC activities and intellectual property.  Prior to joining Aradigm, David worked at Genentech, Inc. (1988 to 1996) developing and characterizing the delivery of protein aerosols to the airways, culminating with the approval of Pulmozyme® rhDNase for the management of cystic fibrosis in 1993. David holds a chemical engineering degree from MIT (SB) and UC Davis (MS) and a pharmacy degree from the University of Sydney (PhD).